Danaher Corporation $DHR Shares Bought by Adalta Capital Management LLC

by · The Cerbat Gem

Adalta Capital Management LLC raised its position in Danaher Corporation (NYSE:DHR – Free Report) by 30.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,919 shares of the conglomerate’s stock after acquiring an additional 2,062 shares during the quarter. Danaher accounts for about 1.0% of Adalta Capital Management LLC’s investment portfolio, making the stock its 24th largest holding. Adalta Capital Management LLC’s holdings in Danaher were worth $1,831,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Arete Wealth Advisors LLC grew its position in Danaher by 6.2% in the first quarter. Arete Wealth Advisors LLC now owns 4,973 shares of the conglomerate’s stock valued at $1,020,000 after acquiring an additional 292 shares in the last quarter. Clearline Capital LP acquired a new stake in Danaher in the first quarter valued at approximately $1,514,000. Caxton Associates LLP acquired a new stake in Danaher in the first quarter valued at approximately $421,000. Hamilton Capital LLC grew its position in Danaher by 78.4% in the first quarter. Hamilton Capital LLC now owns 1,559 shares of the conglomerate’s stock valued at $320,000 after acquiring an additional 685 shares in the last quarter. Finally, Sciencast Management LP acquired a new stake in shares of Danaher during the first quarter worth approximately $205,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DHR. Robert W. Baird raised their price target on shares of Danaher from $225.00 to $226.00 and gave the stock an “outperform” rating in a research report on Friday, July 18th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Guggenheim restated a “buy” rating and set a $250.00 price objective on shares of Danaher in a research note on Wednesday, July 23rd. Scotiabank raised shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price target for the company in a report on Friday, July 11th. Finally, UBS Group reduced their price target on shares of Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $246.35.

Get Our Latest Stock Analysis on Danaher

Insider Transactions at Danaher

In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.20% of the stock is currently owned by insiders.

Danaher Price Performance

NYSE:DHR opened at $200.32 on Monday. The business’s 50-day moving average price is $201.93 and its 200 day moving average price is $199.31. The firm has a market cap of $143.44 billion, a P/E ratio of 42.62, a PEG ratio of 2.79 and a beta of 0.75. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher’s revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read More